Our mission is to develop a novel approach to ADHD

Developing Centanafadine for ADHD:
May have Efficacy Profile comparable to Stimulants,*
May have Abuse Liability less than Stimulants,**
Potential for Less Restrictive Scheduling

*Based on a comparison to the range of effect-size reported in previously published trials with stimulants. There have not been head-to-head studies to-date

**Based on a single Human Abuse Liability study

Neurovance – a clinical stage neuroscience-focused companyNeurovance is a clinical stage neuroscience-focused company. Following the successful development of centanafadine (formerly EB-1020) for adult ADHD, Neurovance plans to develop centanafadine for adolescents and younger children with ADHD.

Hypothesis-driven, proprietary research at Neurovance discovered and developed centanafadine (CTN). Positive results from the first phase 2a clinical trial suggested efficacy and safety in adult ADHD, and a human abuse liability study suggests lower abuse potential and therefore the potential for lower scheduling for CTN compared to stimulants used to treat adult ADHD.

ADHD is not just restless children. Studies show that adult drivers with ADHD are more likely to be in a serious car crash. Other research indicates that ADHD results in impulsiveness and impaired judgment that can increase problems ranging from unemployment to substance abuse to unwanted pregnancy. Untreated ADHD in adults makes navigating through life a significant challenge.